Deputy Director, Cancer Science Institute Singapore, National University of Singapore (NUS), Adjunct: Yong Loo Lin Professor of Medical Oncology, Yong Loo Lin School of Medicine, NUS
経歴
1968 MD PhD, Tohoku University Graduate School of Medical Sciences
1969 Research Associate, Department of Microbiology and Immunology Duke University Medical Center, NorthCarolina, USA
1975 Scientifi c Staff , Department of Cell Regulation Imperial Cancer Research Fund Laboratories, London, England
1984 Professor, Laboratory of Cell Regulation, Department of Viral Oncology Institute for Virus Research, KyotoUniversity, Kyoto, Japan
(1995 ‒ 2001 Director, Institute for Virus Research, Kyoto University, Kyoto, Japan)
2002‒ Principal Investigator, Professor, Institute of Molecular and Cell Biology Director, Oncology Research Institute, NUS
2008‒ Deputy Director, Cancer Science Institute of Singapore, NUS Adjunct Professor, Institute of Molecular and Cell Biology Yong Loo Lin Professor of Medical Oncology, Department of Medicine, Yong Loo Lin School of Medicine, NUS
研究テーマ
My research interest is molecular mechanisms of carcinogenesis with particular emphasis on RUNX genes. I am one of the founders of the RUNX research field. We found RUNX1 is guardian of hematopoietic stem cells. RUNX3 is involved in many cancers as a tumor suppressor and, in some cases, as an oncogene. We found that RUNX3 is an integral component of TGF- tumor suppressor pathway and attenuator of Wnt signaling. I plan to establish collaborations with researchers in GCOE members, many of whom I know quite well. In addition, I will be a liaison person to link GCOE members to various branches within Singapore, especially, to Singapore Institute of Clinical Science, headed by Prof Judith Swain, who is specialized in metabolic diseases.
主要業績
Ito K, Chuang LS, Ito T, Chang TL, Fukamachi H, Salto-Tellez
M, Ito Y. Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology. 2011 Jan 27 [Epub ahead of print]
Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS,
Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H, Ito Y. RUNX3 Attenuates beta-Catenin/T Cell Factors in Intestinal Tumorigenesis. Cancer Cell. 14(3): 226-37 (2008).
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C,
Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y. RUNX3, a novel tumor suppressor, is highly inactivated in gastric cancer by protein mislocalization. Cancer Res. 65(17): 7743-50 (2005).
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee
KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Casual Relationship between the Loss of RUNX3 Expression and Gastric Cancer. Cell. 109(1): 113-24 (2002).
